Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CD8B family member 2 (CD8B2), also known as "putative T-cell surface glycoprotein CD8 beta-2 chain," is classified as a pseudogene in humans[5][6]. A pseudogene is a DNA sequence similar to a functional gene but generally non-functional due to mutations or lack of expression. While the canonical CD8B gene encodes the beta subunit of the CD8 molecule, which is a vital co-receptor on cytotoxic T lymphocytes involved in immune responses[1][2], CD8B2 is not established as a functional gene or as a receptor/therapeutic target. The function and relevance of the CD8B2 gene product are not clearly supported, with multiple gene and protein databases annotating it as a pseudogene or as a putative, non-evidenced protein product[5][6]. There are no established biological or disease roles, drug interactions, or clinical utility for CD8B2, and no evidence supports its use as a biomarker or therapeutic target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CD8B family member 2 (CD8B2).